Description
Key facts
Cell type:A549,
Species or organism:Human,
Tissue:Lung,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 11 bp deletion in exon2 and 1 bp deletion in exon2.,
Disease:Carcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-IFIT3, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
IFIT3 also known as P60 is a member of the IFIT (Interferon-Induced Proteins with Tetratricopeptide Repeats) family of proteins. With a molecular mass of approximately 60 kDa IFIT3 is part of the antiviral response system. This protein is expressed in various tissues and is highly inducible by type I interferons. It functions to inhibit viral replication by interacting with viral RNA. The structure of IFIT3 includes tetratricopeptide repeat motifs which facilitate its role in protein-protein interactions.
Biological function summary
IFIT3 plays a major role in the immune response against viral infections. The protein forms complexes with other IFIT family members like IFIT1 and IFIT2 to enhance antiviral efficacy. IFIT3 binds to foreign RNA lacking proper cap structures blocking viral protein synthesis. The protein's actions help strengthen the innate immune system and further control the spread of viral pathogens. IFIT3 also modulates cellular functions by engaging with signaling pathways that regulate inflammation and immune defense.
Pathways
IFIT3 integrates into important signaling networks such as the interferon-mediated signal transduction pathway and the JAK-STAT signaling pathway. In these pathways IFIT3 along with related proteins like IRF3 and ISG15 helps amplify immune responses after detecting viral threats. Its involvement in these pathways ensures that antiviral states within cells are quickly established reducing viral survival and dissemination.
IFIT3 has significant implications for infection and cancer outcomes. In viral infections such as hepatitis C IFIT3 expression levels correlate with effective antiviral activity and prognosis. In cancer aberrant IFIT3 expression can influence tumorigenesis and impact treatment responses. Collaborating with proteins such as STAT1 and p53 IFIT3 can affect pathways involved in cell proliferation and apoptosis linking immune responses to cancer progression and therapy resistance.
